Arcus data throw TIGIT a lifeline: Clinical Report

In a week light on stock-moving readouts, Arcus stood out for Phase II results that could revive interest in the once-promising checkpoint target TIGIT, while shares of Tvardi took a hit on a Phase II miss in idiopathic pulmonary fibrosis and Astellas’ CLDN18.2 mAb missed an expansion opportunity.

Arcus Biosciences Inc. (NYSE:RCUS) rose 14% after reporting a median overall survival of 26.7 months in the Phase II EDGE-Gastric study of anti-TIGIT mAb domvanalimab, in combination with an anti-PD-1 mAb and chemotherapy, to treat gastroesophageal adenocarcinomas. ...